Year: 2022

The Centers for Medicare & Medicaid Services Makes Preliminary Recommendation to Establish New HCPCS Billing Code Dedicated to Arch Therapeutics’ AC5® Advanced Wound System

Written by Customer Service on December 5, 2022. Posted in Public Companies.

A dedicated code would represent a key milestone for commercialization of AC5 Advanced Wound System in doctors’ offices and other outpatient settings FRAMINGHAM, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical products, today announced that the Centers for Medicare and Medicaid Services (“CMS”) has made a preliminary recommendation to establish a dedicated Healthcare Common Procedure Coding System (“HCPCS”) Level II billing code specific to AC5® Advanced Wound System (“AC5”). The preliminary recommendation was discussed at CMS’ First Biannual 2022 HCPCS Public Meeting, which was held on November 30, 2022. The HCPCS code would better enable providers to bill third party payors for AC5 that is used...

Selection of candidates for independent Audit Committee member and Remuneration and Nomination Committee member of AB Klaipėdos nafta is announced

Written by Customer Service on December 5, 2022. Posted in Public Companies.

On 5th August, 2022, AB Klaipėdos nafta (hereinafter – the Company), announced a selection of candidates for independent members of the Audit Committee and Remuneration and Nomination Committee under Supervisory Council (hereinafter – Committees) of the Company. The selection is announced for one independent member of the Audit Committee of the Company and for one independent member of the Remuneration and Nomination Committee of the Company. The selection shall be performed according to the Schedule for the selection of independent members of the Audit Committee and Remuneration and Nomination Committee of AB Klaipėdos nafta, approved by the 24th November, 2022 decision of the Supervisory Council of the Company. After the selection procedures are performed, the members of the Committees shall be elected by the Supervisory Council of the...

Form 8.3 – [Devro plc – 02 12 2022] – (CGWL)

Written by Customer Service on December 5, 2022. Posted in Mergers And Acquisitions.

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree DEVRO PLC(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e) Date position held/dealing...

Lilium expands into UK market with eVolare, signs binding contract including pre-delivery payment for up to 20 aircraft

Written by Customer Service on December 5, 2022. Posted in Public Companies.

Lilium expands into UK market with eVolare and the Lilium Pioneer Edition The Lilium Pioneer Edition, which formally launches today, is a 50 aircraft limited-edition exclusive version of the Lilium Jet. Find out more: Link to press release #Lilium #eVTOLeVolare secures deliveries of ten Lilium Pioneer Edition Jets with an option to reserve up to an additional ten Lilium Pioneer Edition Jets eVolare to serve the Greater London area from its Oxford base eVolare to pay pre-delivery payment to Lilium to secure aircraft delivery slots The order coincides with the formal launch of the Lilium Pioneer Edition, a 50 aircraft limited-edition exclusive version of the Lilium JetOXFORD, United Kingdom and MUNICH, Germany, Dec. 05, 2022 (GLOBE NEWSWIRE) — Lilium N.V. (NASDAQ: LILM), developer of the first all-electric vertical take-off...

HilleVax Announces Positive Immunogenicity Results for Run-In Cohort of NEST-IN1 Phase 2b Clinical Trial of HIL-214 Norovirus Vaccine Candidate

Written by Customer Service on December 5, 2022. Posted in Public Companies.

BOSTON, Dec. 05, 2022 (GLOBE NEWSWIRE) — HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, today reported results from a prespecified immunogenicity analysis of the 203 subjects enrolled in the run-in cohort of NEST-IN1 (Norovirus Efficacy and Safety Trial for INfants), the company’s ongoing Phase 2b trial for HIL-214, its investigational virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe norovirus-related acute gastroenteritis (AGE) in infants. These results follow the previously announced positive recommendation from an independent safety data monitoring committee based on this same cohort. Immunogenicity Results:Geometric Mean Titers (GMTs) of pan-IG antibodies 28 days following the second dose were 11,102.0...

Veru Reports Fiscal 2022 Fourth Quarter and Full Year Financial Results

Written by Customer Service on December 5, 2022. Posted in Public Companies.

U.S. FDA reviewing EUA application for sabizabulin to treat hospitalized COVID-19 patients at high risk for ARDS European Medicines Agency’s (EMA) Emergency Task Force reviewing sabizabulin for emergency use in EU member states Sabizabulin also under review for potential emergency authorization by MHRA (UK), TGA (Australia), and Health Canada Veru preparing for U.S. and international commercialization and distribution of sabizabulin, and manufacturing capacity for drug supply in place Company to host conference call and webcast today at 8:00 a.m. ET MIAMI, FL, Dec. 05, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced financial results for its fiscal 2022 fourth quarter and full...

Wireless Telecom Group Announces the Sale of CommAgility, its Radio, Baseband and Software Segment, to E-Space

Written by Customer Service on December 5, 2022. Posted in Public Companies.

Parsippany, New Jersey, USA, Dec. 05, 2022 (GLOBE NEWSWIRE) — Wireless Telecom Group, Inc. (NYSE American: WTT) (the “Company”) today announced it entered into a definitive agreement to sell its radio, baseband and software segment, CommAgility LTD., to global space company, E-Space. The purchase price is $14.5 million, inclusive of $13.75 million in cash consideration and a $750,000 note payable, subject to agreed-upon reductions. The transaction was the result of the Company’s previously disclosed process for evaluating strategic alternatives. The Purchase Agreement includes customary terms and conditions, including certain adjustments to the purchase price based on transaction costs, net working capital and indebtedness. The transaction, which was unanimously approved by the Board of Directors of both companies, is subject to...

TFF Pharmaceuticals Announces Leadership Transition

Written by Customer Service on December 5, 2022. Posted in Public Companies.

Glenn Mattes to step down as Chief Executive Officer and as a Member of the Board of Directors Dr. Harlan F. Weisman, Vice Chairman of the Board, appointed as Interim Chief Executive Officer FORT WORTH, Texas, Dec. 05, 2022 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing technology platform, today announced that Glenn Mattes will step down as Chief Executive Officer and Member of the Board of Directors. Dr. Harlan F. Weisman, Vice Chairman of the Board, has been appointed Interim Chief Executive Officer, effective December 5, 2022. “On behalf of the entire Board of Directors and our shareholders, I would like to thank Glenn for his leadership and accomplishments,” said...

With 15.1% CAGR, Orthokeratology Lens Market Size to Surpass Around USD 2,043.6 Billion by 2029

Written by Customer Service on December 5, 2022. Posted in Mergers And Acquisitions.

According to Fortune Business Insights, Orthokeratology Lens Market to Reach USD 2,043.6 Billion by 2029; Increasing Awareness Regarding the Benefits Associated with the Lens to Propel Industry Growth Pune, India, Dec. 05, 2022 (GLOBE NEWSWIRE) — The global orthokeratology lens market size was valued at USD 683.5 million in 2021. The market is expected to grow from USD 763.9 million in 2022 to USD 2,043.6 million by 2029, exhibiting a CAGR of 15.1% during the forecast period. The increasing prevalence of refractive errors among the population and rising awareness regarding the lenses’ benefits are expected to enhance the market growth. Fortune Business Insights™ presents this information in its report titled “Orthokeratology Lens Market, 2022-2029.”Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/orthokeratology-lens-market-103110Key...

Waterjet Cutting Machines Market Size to Hit USD 1,675.1 Million by 2027 | Exhibit a CAGR of 6.3%

Written by Customer Service on December 5, 2022. Posted in Mergers And Acquisitions.

The global waterjet cutting machines market size was valued USD 1,036.9 million in 2019. The global market size is projected to reach USD 1,675.1 Million by 2027; it is estimated to grow at a CAGR of 6.3% from 2020 to 2027. Pune, India, Dec. 05, 2022 (GLOBE NEWSWIRE) — The global waterjet cutting machines market size is expected to grow from USD 1,036.9 million in 2019 and is projected to reach USD 1,675.1 Million by 2027, exhibiting a CAGR of 6.3% during the forecast period from 2020-2027. This information is provided by Fortune Business Insights, in its report, titled, “Waterjet Cutting Machines Market, 2020-2027.” According to our analysts, the market size is set to gain momentum from the rising need for quick diagnosis of the consumer’s problems. Companies are trying to fix them in real-time. They are also focusing more on...

Year: 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals